GNC-035

DRUG5 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

Breast CancerHematologic MalignanciesNon-hodgkin's LymphomaRelapsed/Refractory Chronic Lymphocytic LeukemiaSolid Tumor

Phase 1

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

WithdrawnNCT05039931

Sichuan Baili Pharmaceutical Co., Ltd.Breast Cancer, Solid Tumor

Start: 2021-09-15End: 2023-06-30Updated: 2024-07-18

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Active, not recruitingNCT05104775

Sichuan Baili Pharmaceutical Co., Ltd.Hematologic Malignancies

Start: 2022-02-09End: 2025-12-31Updated: 2025-09-26

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Active, not recruitingNCT05160545

Sichuan Baili Pharmaceutical Co., Ltd.Breast Cancer

Start: 2021-11-26End: 2025-12-31Updated: 2025-09-26

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Active, not recruitingNCT05944978

Sichuan Baili Pharmaceutical Co., Ltd.Relapsed/Refractory Chronic Lymphocytic Leukemia

Start: 2023-08-16End: 2025-12-31Updated: 2025-09-26

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

RecruitingNCT06066203

Sichuan Baili Pharmaceutical Co., Ltd.Non-hodgkin's Lymphoma

Start: 2023-11-01End: 2027-12-01Target: 40Updated: 2026-08-27